What is the current stock price of Phio Pharmaceuticals Corp. (PHIO)?

As of the latest market data, Phio Pharmaceuticals Corp. (PHIO) is trading at $1.10. The stock has seen a gain of 1.85% today.

Does Phio Pharmaceuticals Corp. (PHIO) pay a dividend?

Based on current data, Phio Pharmaceuticals Corp. does not have a confirmed active dividend policy.

What is the market cap of Phio Pharmaceuticals Corp.?

The current market capitalization of Phio Pharmaceuticals Corp. (PHIO) is approximately unavailable.

PHIO

Phio Pharmaceuticals Corp.·Healthcare

1.10

1.852%(+0.02)

Close Price

1.19

8.182%(+0.09)

After Hours

Last Updated: — ET

52W L: $0.8152W H: $4.19

PHIO NEWS

feeds.newsfilecorp.com

1d ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

King of Prussia, Pennsylvania--(Newsfile Corp. - May 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical

feeds.newsfilecorp.com

May 12

Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026

Live virtual fireside chat - investors, advisors, and life sciences analysts invited to attendFeaturing Dermatologist Mary Spellman, M.D., with Phio

newsfilecorp.com

May 7

Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

Completion of Lead Clinical Candidate PH-762 Dose Escalation Trial for Treatment of Skin Cancer with Favorable Safety and Pathology Data Key Development Agreements Secured for Nonclinical Toxicology and U.S. cGMP Clinical Supply Manufacturing King of Prussia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio today reported its financial results for the quarter ended March 31, 2026, and provided a business update.

feeds.newsfilecorp.com

Apr 23

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

King of Prussia, Pennsylvania--(Newsfile Corp. - April 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical

newsfilecorp.com

Apr 13

Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026

Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend this virtual event R. Todd Plott, M.D.

feeds.newsfilecorp.com

Apr 9

Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - April 9, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical

Company Profile

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2012-05-10

Beta

0.84

Websitewww.phiopharma.com↗